tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Muscular Dystrophies D009136 10 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Glycosuria D006029 10 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Fatigue D005221 10 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Long QT Syndrome D008133 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Vision Disorders D014786 10 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Dyspnea D004417 10 associated lipids
Hemophilia A D006467 10 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Sinusitis D012852 9 associated lipids
Cicatrix D002921 9 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Leukocytosis D007964 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Urination Disorders D014555 9 associated lipids
Hypertension, Renal D006977 9 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Lupus Nephritis D008181 8 associated lipids
Thyroid Diseases D013959 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Opportunistic Infections D009894 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Dyslipidemias D050171 7 associated lipids
Chronic Disease D002908 7 associated lipids
Metaplasia D008679 7 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Hepatitis C D006526 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Dementia, Vascular D015140 7 associated lipids
Facial Dermatoses D005148 7 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Tachycardia D013610 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Folliculitis D005499 7 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Infection D007239 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Pancytopenia D010198 6 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Graves Disease D006111 6 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Angioedema D000799 6 associated lipids
Gynecomastia D006177 6 associated lipids
Thrombophlebitis D013924 6 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Heart Injuries D006335 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Liver Abscess D008100 6 associated lipids
Pericarditis D010493 6 associated lipids
Blindness D001766 6 associated lipids
Alopecia Areata D000506 6 associated lipids
Gliosis D005911 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Respiration Disorders D012120 5 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Postoperative Complications D011183 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Sclerosis D012598 5 associated lipids
Mastocytosis D008415 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Tinea D014005 5 associated lipids
Mouth Diseases D009059 5 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Liver Failure D017093 5 associated lipids
Osteomalacia D010018 5 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Trypanosomiasis D014352 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Hematoma D006406 5 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Suzuki H et al. Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. 1997 Transplantation pmid:9293881
Asberg A et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. 2006 Transplantation pmid:16861943
Kuypers DR et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. 2010 Transplantation pmid:20555228
Yang CW et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. 2001 Transplantation pmid:11740384
Moxey-Mims MM Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1999 Transplantation pmid:10440413
McGhee B et al. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. 1997 Transplantation pmid:9326429
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Firdaous I et al. Pediatric intravenous FK506--how much are we really infusing? 1994 Transplantation pmid:7517079
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Tuteja S et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. 2001 Transplantation pmid:11397967
Reichenspurner H et al. Optimization of the immunosuppressive protocol after lung transplantation. 1999 Transplantation pmid:10428269
Pilmore HL et al. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. 2001 Transplantation pmid:11726837
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Murase N et al. FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. 1990 Transplantation pmid:1700504
Størset E et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. 2015 Transplantation pmid:25886918
Shapiro R et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. 1999 Transplantation pmid:10075598
Kaplan B et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. 1999 Transplantation pmid:10075604
Erden E et al. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. 1994 Transplantation pmid:7519801
Morikawa K et al. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. 1992 Transplantation pmid:1281561
Jain A et al. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. 2000 Transplantation pmid:10653398
Kihm LP et al. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. 2012 Transplantation pmid:22470107
Ninova D et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. 2004 Transplantation pmid:15316360
Ciancio G et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. 2004 Transplantation pmid:15316372
Xie Y et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. 2017 Transplantation pmid:28187014
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Sarwal MM et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. 2003 Transplantation pmid:14627912
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Vignali D et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. 2016 Transplantation pmid:27306531
Berg UB et al. Renal function before and long after liver transplantation in children. 2001 Transplantation pmid:11544422
Gruessner RW et al. Mycophenolate mofetil in pancreas transplantation. 1998 Transplantation pmid:9721799
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Nankivell BJ et al. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. 2016 Transplantation pmid:27306529
Marin-Casino M et al. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. 2014 Transplantation pmid:25243519
Reich DJ et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. 2005 Transplantation pmid:16003228
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Dhar DK et al. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. 1992 Transplantation pmid:1384188
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368
Yilmaz MI et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. 2005 Transplantation pmid:16378057
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241